We would love to hear your thoughts about our site and services, please take our survey here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCrystal Amber Regulatory News (CRS)

Share Price Information for Crystal Amber (CRS)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 77.00
Bid: 75.00
Ask: 79.00
Change: 0.00 (0.00%)
Spread: 4.00 (5.333%)
Open: 77.00
High: 77.00
Low: 77.00
Prev. Close: 77.00
CRS Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Amendments to the Investment Management Agreement

25 Oct 2023 07:00

RNS Number : 1743R
Crystal Amber Fund Limited
25 October 2023
 

25 October 2023

Crystal Amber Fund Limited

("Crystal Amber Fund" or the "Fund")

 

Amendments to the Investment Management Agreement

 

Crystal Amber Fund announces that it has reached agreement to amend the investment management agreement ("IMA") with Crystal Amber Asset Management (Guernsey) Limited (the "Investment Manager"). The amendment will provide for the continuation of management fees to the Investment Manager beyond 31 December 2023.

 

Background to the revised IMA

 

The current IMA does not provide for a management fee for the Investment Manager after 31 December 2023. As the services of the Investment Manager are expected to be required beyond 31 December 2023, the Fund has agreed an amendment to the IMA to provide for monthly fees from 1 January 2024, subject to regular review. 

 

Following a change in strategy, the current IMA fee arrangement was agreed in March 2022 and on the assumption that by the end of 2023, the Fund's portfolio would be predominantly realised (with the probable exception of Morphic Medical) and therefore there would be little management of the portfolio required. 

 

Since that time, the Investment Manager has achieved several successful exits, all at premiums to carrying values at March 2022. Most notably, the strategic holdings in Hurricane Energy plc and Equals Group plc have been monetised. In the case of Hurricane Energy plc, as well as receiving proceeds of £36.5 million, the Fund continues to own Deferred Consideration Units. In view of the intensive activism required for the Fund's shareholding in De La Rue plc and the ongoing requirement to maximise shareholder returns in an orderly manner, the Board believes that it remains in the best interests of the Fund to retain the services of the Investment Manager until the Fund's portfolio is realised.

 

The Fund has today published its annual report and accounts which provides current details of the Fund's portfolio. The Board of the Fund remains focused on realising the portfolio as efficiently as possible in order to achieve optimum returns for shareholders.

 

As stipulated by the Company's Investment Policy, should any of the Company's investments remain unrealised at 31 December 2023, the Board is required to consider consulting shareholders and/or make arrangements to seek shareholder approval on the future strategy of the Company, including any steps that might be necessary to maximise the opportunity to realise value from the remaining assets of the Company. 

 

Current fee structure

 

Under the current IMA, the Investment Manager receives a management fee totaling £690,000 in 2023, to be paid on a monthly basis as set out below:

 

- 1 January 2023 to 30 June 2023: £70,000 per month;

- 1 July 2023 to 30 September 2023: £50,000 per month; and

- 1 October 2023 to 31 December 2023: £40,000 per month.

 

In addition, the Investment Manager is currently entitled to receive a performance fee of 20% of the aggregate return of cash paid to Shareholders after 1 January 2022 over a hurdle of £216 million. This performance fee will remain in place.

 

Revised fee structure

 

Due to the requirement of the Fund to have active portfolio management going into 2024, the Board has agreed for the Fund to continue paying a monthly management fee to the Investment Manager on the basis of the fees paid in 2023. Accordingly, the IMA will be amended such that from 1 January 2024, the monthly fee due to the Investment Manager will be £57,500 (£690,000 annually, as per 2023). On an annual basis, this fee equates to approximately 0.83% of the current NAV.

 

The monthly management fee will be subject to review by the Fund on one month's notice and will be formally reviewed by the Board with the half year financial results of the Fund in March 2024 and at regular intervals thereafter. Therefore, this will provide flexibility for the Fund, depending on the status of the portfolio in the future and progress with realisations.

 

The Board believes that continuing the monthly management fee on this basis is appropriate in the circumstances.

 

Pursuant to the AIM Rules for Companies, the Investment Manager is deemed to be a related party of the Company and the agreement to amend the IMA is therefore deemed to be a related party transaction. The Directors consider, having consulted with Allenby Capital Limited, the Company's Nominated Adviser, that the agreement is fair and reasonable insofar as Shareholders are concerned.

 

 

Contacts:

 

Crystal Amber Fund Limited

Chris Waldron (Chairman)

Tel: 01481 742 742

www.crystalamber.com

 

Allenby Capital Limited - Nominated Adviser

Jeremy Porter/ Dan Dearden-Williams

Tel: 020 3328 5656

 

Winterflood Investment Trusts - Broker

Joe Winkley/Neil Langford

Tel: 020 3100 0160

 

Crystal Amber Advisers (UK) LLP - Investment Adviser

Richard Bernstein

Tel: 020 7478 9080

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
AGRDZMZGLDLGFZM
Date   Source Headline
29th Apr 20243:26 pmRNSHolding(s) in Company
26th Apr 20245:27 pmRNSTransaction in Own Shares
25th Apr 20247:00 amRNSHolding(s) in Company
24th Apr 20244:00 pmRNSMonthly Net Asset Value
24th Apr 20247:00 amRNSTransaction in Own Shares
12th Apr 20246:22 pmRNSTransaction in Own Shares
10th Apr 20249:34 amRNSTransaction in Own Shares
3rd Apr 20244:44 pmRNSMonthly Net Asset Value
3rd Apr 20247:00 amRNSTransaction in Own Shares
2nd Apr 20241:30 pmRNSExtension to Share Buyback Programme
28th Mar 20246:01 pmRNSTotal Voting Rights
28th Mar 20247:00 amRNSHalf-year Report
27th Mar 20246:27 pmRNSTransaction in Own Shares
22nd Mar 20245:09 pmRNSTransaction in Own Shares
18th Mar 20245:29 pmRNSTransaction in Own Shares
18th Mar 20247:00 amRNSTransaction in Own Shares
13th Mar 20245:30 pmRNSTransaction in Own Shares
11th Mar 20244:59 pmRNSTransaction in Own Shares
7th Mar 20245:38 pmRNSTransaction in Own Shares
29th Feb 20245:30 pmRNSTotal Voting Rights
27th Feb 20247:00 amRNSNotice of Interim Results and Portfolio Update
27th Feb 20247:00 amRNSDirector/PDMR Dealing
26th Feb 20244:45 pmRNSTransaction in Own Shares
26th Feb 20247:00 amRNSTransaction in Own Shares
22nd Feb 20246:02 pmRNSTransaction in Own Shares
22nd Feb 20249:28 amRNSMonthly Net Asset Value
22nd Feb 20247:00 amRNSTransaction in Own Shares
19th Feb 20247:00 amRNSTransaction in Own Shares
14th Feb 20245:20 pmRNSTransaction in Own Shares
13th Feb 20245:41 pmRNSHolding(s) in Company
2nd Feb 20246:17 pmRNSTransaction in Own Shares
1st Feb 20246:14 pmRNSTransaction in Own Shares
1st Feb 20247:00 amRNSTotal Voting Rights and Transaction in Own Shares
30th Jan 20249:47 amRNSHolding(s) in Company
30th Jan 20249:41 amRNSHolding(s) in Company
29th Jan 20245:20 pmRNSExtension to Share Buyback Programme
26th Jan 20245:47 pmRNSTransaction in Own Shares
25th Jan 20247:00 amRNSReplacement - Director/PDMR Shareholding
24th Jan 20245:32 pmRNSTransaction in Own Shares
24th Jan 20249:01 amRNSDirector/PDMR Shareholding
24th Jan 20248:22 amRNSDirector/PDMR Shareholding
23rd Jan 20245:45 pmRNSTransaction in Own Shares
23rd Jan 20247:00 amRNSHolding(s) in Company
22nd Jan 20245:37 pmRNSTransaction in Own Shares
22nd Jan 20244:38 pmRNSMonthly Net Asset Value
19th Jan 20247:00 amRNSTransaction in Own Shares
17th Jan 20245:30 pmRNSTransaction in Own Shares
16th Jan 20245:34 pmRNSTransaction in Own Shares
15th Jan 20245:31 pmRNSTransaction in Own Shares
11th Jan 20245:17 pmRNSTransaction in Own Shares

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.